KYMR vs BMRN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KYMR · Kymera Therapeutics$115.31 ▼ 3.42%
BMRN · Biomarin Pharmaceutical$60.41 ▼ 1.64%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KYMR +75.8%
- BMRN +8.8%
Head to head
| Metric | KYMR | BMRN |
|---|---|---|
| Price | $115.31 | $60.41 |
| Change today | ▼ 3.42% | ▼ 1.64% |
| Market cap | $9.84B | $11.70B |
| Return, 3 months | -4.7% | -7.2% |
| Return, year to date | +48.2% | +1.6% |
| Return, 1 year | +74.6% | +10.5% |
| P/E (TTM) | – | – |
| P/B | 6.1 | 1.9 |
| P/E percentile vs own 5y | 3rd | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | +32.0% |
| Net profit growth (YoY) | -60.6% | -299.5% |
| Gross margin | – | 76.0% |
| Operating margin | -396.0% | 4.9% |
| Net margin | -341.8% | -0.5% |
| Return on equity | -27.3% | -0.3% |
| Analyst target vs. price | +30.7% | +46.9% |
| Analyst buy share | 100% | 74% |
| RSI (14) | 41 | 59 |
| 30-day volatility | 51.7% | 31.8% |
| Max drawdown, 1 year | -27.7% | -22.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BMRN is the largest of the group by market value.
- KYMR has returned the most over the past year.
- BMRN is growing revenue fastest.
- BMRN keeps the most profit per dollar of sales.
- BMRN has been the calmest stock over the last 30 days.